Director Baluch Khoso of Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) purchased 2,269 shares of the company's common stock on March 31, 2026, at a price of $2.535 per share. The purchase amounted to $5,751 in total. Following the acquisition, Khoso directly owns 2,325 shares of Processa Pharmaceuticals.
The company is currently trading at $2.60 a share and carries a market capitalization of $6.97 million. Over the past week the stock has returned 9.78%, although it remains down 75% versus its level a year ago.
Market research from InvestingPro, which is noted to offer 11 additional exclusive tips for PCSA, indicates that Processa holds more cash than debt on its balance sheet. At the same time, InvestingPro rates the firm's overall financial health score as weak.
Clinical progress
In recent corporate developments, Processa has completed enrollment and dosing of 20 patients for an interim analysis in its Phase 2 clinical trial of NGC-Cap, a therapy being evaluated for advanced or metastatic breast cancer. NGC-Cap is a combination regimen that pairs PCS6422 with capecitabine and is being tested against standard capecitabine monotherapy.
The patients included in this cohort had undergone at least one prior cancer treatment, with a median of two to three previous regimens. The company describes the completion of these 20 patients for interim analysis as a notable milestone in its ongoing research program. The outcome of the interim analysis could have implications for the development path of NGC-Cap and Processa's clinical pipeline.
Context and next steps
The insider purchase by Khoso and the completion of the 20-patient dosing for interim analysis are part of Processa's current corporate activity. Observers will likely monitor the interim analysis results and the company's financial metrics as reported by sources such as InvestingPro. Given the company's modest market capitalization and the mixed balance sheet signal noted by InvestingPro, both the market reaction to clinical updates and the company's capital position will be relevant factors for investors and stakeholders.